RxDoctor Payments Data

Christopher Longnecker, MD

Cardiovascular Disease · Joplin, MONPI 1255334777

Payments from drug & device makers

$30,190in general payments, 2019–2025

Across 130 payments — averaging $232.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$9K
  • Medtronic$5K
  • Biogen$5K
  • E.r. Squibb & Sons, L.L.C.$4K
  • Boston Scientific$4K
  • Edwards Lifesciences$2K
  • plus $2K from 9 others

What the payments were for

  • Consulting fees$7,68027%
  • Speaking & faculty fees$6,95024%
  • Travel & lodging$9,77634%
  • Food & beverage$4,22515%
  • Education$620%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$30,190 in reported general payments places this provider in the 80th percentile of 391 cardiovascular disease providers in Missouri.

See all cardiovascular disease providers in Missouri

Medicare billing

Part B allowed, 2024
$313,907
Medicare patients
1,574
Services billed
5,109

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban976$927,412
EntrestoSacubitril/Valsartan183$210,755
XareltoRivaroxaban221$197,118
JardianceEmpagliflozin153$113,299
FarxigaDapagliflozin Propanediol72$67,809
Repatha SureclickEvolocumab43$30,896
Praluent PenAlirocumab27$18,719
BrilintaTicagrelor14$14,830
VascepaIcosapent Ethyl32$12,440
MultaqDronedarone Hcl12$11,667
Dofetilide43$10,277
Metoprolol Succinate824$10,160
Diltiazem 24hr Er (Cd)Diltiazem Hcl383$9,776
Isosorbide Mononitrate ErIsosorbide Mononitrate949$9,362
Valsartan525$9,032

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Brilinta$18$82,63986 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 391 cardiovascular disease providers in Missouri.

Other cardiovascular disease in Joplin

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →